- Home
- NXTC vs IBIO Comparison
NXTC vs IBIO Comparison
Compare NXTC & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- IBIO
- Stock Information
- Founded
- NXTC 2015
- IBIO 2008
- Country
- NXTC United States
- IBIO United States
- Employees
- NXTC N/A
- IBIO N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- IBIO Health Care
- Exchange
- NXTC Nasdaq
- IBIO Nasdaq
- Market Cap
- NXTC 13.9M
- IBIO 9.3M
- IPO Year
- NXTC 2019
- IBIO N/A
- Fundamental
- Price
- NXTC $0.49
- IBIO $0.77
- Analyst Decision
- NXTC Strong Buy
- IBIO Strong Buy
- Analyst Count
- NXTC 2
- IBIO 3
- Target Price
- NXTC $3.50
- IBIO $4.87
- AVG Volume (30 Days)
- NXTC 141.9K
- IBIO 776.1K
- Earning Date
- NXTC 05-01-2025
- IBIO 05-02-2025
- Dividend Yield
- NXTC N/A
- IBIO N/A
- EPS Growth
- NXTC N/A
- IBIO N/A
- EPS
- NXTC N/A
- IBIO N/A
- Revenue
- NXTC N/A
- IBIO $375,000.00
- Revenue This Year
- NXTC N/A
- IBIO $36.00
- Revenue Next Year
- NXTC N/A
- IBIO N/A
- P/E Ratio
- NXTC N/A
- IBIO N/A
- Revenue Growth
- NXTC N/A
- IBIO 650.00
- 52 Week Low
- NXTC $0.22
- IBIO $0.64
- 52 Week High
- NXTC $1.82
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- NXTC 55.20
- IBIO 30.08
- Support Level
- NXTC $0.45
- IBIO $0.70
- Resistance Level
- NXTC $0.52
- IBIO $0.83
- Average True Range (ATR)
- NXTC 0.05
- IBIO 0.06
- MACD
- NXTC 0.01
- IBIO 0.08
- Stochastic Oscillator
- NXTC 66.47
- IBIO 41.18
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.